

Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

**Table 01: Study population and enrolment information
Full Analysis Dataset : BELGIUM**

Number of prospective patients (C1+C2+C3+C4+C5)	1694
Number of enrolling sites	25
Number of enrolling countries	1
Enrolment period	08MAY2012 - 26JUL2016
Duration of enrolment (months)	50.6

**Table 02: Patients by region, country, and cohort
Full Analysis Dataset : BELGIUM**

Region	Country	Cohort 2 (N=403)	Cohort 3 (N=515)	Cohort 4 (N=387)	Cohort 5 (N=389)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
Europe	Belgium	403	515	387	389	1694	1305

**Table 03 : Demographic Characteristics
Full Analysis Dataset : BELGIUM**

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
Sex, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	Male	224 (55.6)	303 (58.8)	222 (57.4)	229 (58.9)	978 (57.7)	749 (57.4)
	Female	179 (44.4)	212 (41.2)	165 (42.6)	160 (41.1)	716 (42.3)	556 (42.6)
Age at Diagnosis (Years)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	Mean (SD)	71.6 (11.0)	71.4 (10.8)	70.8 (10.5)	71.4 (10.7)	71.3 (10.7)	71.3 (10.8)
	Median (IQR)	73.0 (65.0 to 80.0)	73.0 (65.0 to 79.0)	72.0 (65.0 to 78.0)	72.0 (65.0 to 80.0)	73.0 (65.0 to 79.0)	73.0 (65.0 to 79.0)
	Min to Max	30 to 91	24 to 95	36 to 93	35 to 94	24 to 95	24 to 95
Age Group, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	<65	93 (23.1)	121 (23.5)	93 (24.0)	93 (23.9)	400 (23.6)	307 (23.5)
	65-74	124 (30.8)	172 (33.4)	137 (35.4)	131 (33.7)	564 (33.3)	433 (33.2)
	>=75	186 (46.2)	222 (43.1)	157 (40.6)	165 (42.4)	730 (43.1)	565 (43.3)
Time since AF Diagnosis (Weeks)	n (missing)	242 (161)	320 (195)	239 (148)	254 (135)	1055 (639)	801 (504)
	Mean (SD)	1.30 (1.56)	1.27 (1.50)	1.41 (1.59)	1.31 (1.68)	1.32 (1.58)	1.32 (1.55)
	Median (IQR)	0.70 (0.20 to 1.70)	0.70 (0.20 to 1.70)	0.70 (0.20 to 2.10)	0.50 (0.20 to 1.80)	0.70 (0.20 to 1.80)	0.70 (0.20 to 1.80)
	Min to Max	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	401 (0)	515 (0)	387 (0)	389 (0)	1692 (0)	1303 (0)
	Caucasian	396 (98.8)	509 (98.8)	387 (100.0)	387 (99.5)	1679 (99.2)	1292 (99.2)
	Hispanic/Latino	3 (0.7)	-	-	-	3 (0.2)	3 (0.2)
	Afro-Caribbean	-	3 (0.6)	-	-	3 (0.2)	3 (0.2)

**Table 03 : Demographic Characteristics
Full Analysis Dataset : BELGIUM**

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
	Asian (Not Chinese)	-	2 (0.4)	-	-	2 (0.1)	2 (0.2)
	Mixed/Other	2 (0.5)	1 (0.2)	-	2 (0.5)	5 (0.3)	3 (0.2)
	Unknown	2	-	-	-	2	2
Region, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	Europe	403 (100.0)	515 (100.0)	387 (100.0)	389 (100.0)	1694 (100.0)	1305 (100.0)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : BELGIUM**

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	Internal Medicine	17 (4.2)	20 (3.9)	9 (2.3)	6 (1.5)	52 (3.1)	46 (3.5)
	Cardiology	345 (85.6)	468 (90.9)	343 (88.6)	322 (82.8)	1478 (87.2)	1156 (88.6)
	Neurology	7 (1.7)	1 (0.2)	5 (1.3)	10 (2.6)	23 (1.4)	13 (1.0)
	Geriatrics	3 (0.7)	6 (1.2)	1 (0.3)	1 (0.3)	11 (0.6)	10 (0.8)
	Primary Care/General Practice	31 (7.7)	20 (3.9)	29 (7.5)	50 (12.9)	130 (7.7)	80 (6.1)
Care Setting Location at Diagnosis, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	Hospital	234 (58.1)	324 (62.9)	239 (61.8)	231 (59.4)	1028 (60.7)	797 (61.1)
	Office	82 (20.3)	110 (21.4)	97 (25.1)	93 (23.9)	382 (22.6)	289 (22.1)
	Emergency room	87 (21.6)	81 (15.7)	51 (13.2)	65 (16.7)	284 (16.8)	219 (16.8)
Type of AF Diagnosed, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	Permanent	8 (2.0)	18 (3.5)	8 (2.1)	8 (2.1)	42 (2.5)	34 (2.6)
	Persistent	86 (21.3)	122 (23.7)	71 (18.3)	63 (16.2)	342 (20.2)	279 (21.4)
	Paroxysmal	100 (24.8)	145 (28.2)	101 (26.1)	94 (24.2)	440 (26.0)	346 (26.5)
	New	209 (51.9)	230 (44.7)	207 (53.5)	224 (57.6)	870 (51.4)	646 (49.5)
Treatment Costs, n(%)	n (missing)	386 (0)	473 (0)	364 (0)	376 (0)	1599 (0)	1223 (0)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : BELGIUM**

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
	Public insurance	276 (71.5)	315 (66.6)	217 (59.6)	210 (55.9)	1018 (63.7)	808 (66.1)
	Private (insurance)	1 (0.3)	16 (3.4)	16 (4.4)	3 (0.8)	36 (2.3)	33 (2.7)
	Private (out of pocket)	2 (0.5)	-	-	-	2 (0.1)	2 (0.2)
	Combination	107 (27.7)	142 (30.0)	131 (36.0)	163 (43.4)	543 (34.0)	380 (31.1)
	Unknown	17	42	23	13	95	82
Treatment Sector, n(%)	n (missing)	398 (0)	515 (0)	386 (0)	389 (0)	1688 (0)	1299 (0)
	In the public sector	257 (64.6)	389 (75.5)	320 (82.9)	309 (79.4)	1275 (75.5)	966 (74.4)
	In the private sector	141 (35.4)	126 (24.5)	66 (17.1)	80 (20.6)	413 (24.5)	333 (25.6)
	Unknown	5	-	1	-	6	6

**Table 05 : Vital signs and life style
Full Analysis Dataset : BELGIUM**

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
Height (cm)	n (missing)	299 (104)	340 (175)	268 (119)	279 (110)	1186 (508)	907 (398)
	Mean (SD)	169.2 (9.9)	169.3 (10.3)	168.5 (9.5)	169.9 (10.3)	169.3 (10.0)	169.0 (9.9)
	Median (IQR)	170.0 (162.0 to 176.0)	170.0 (163.0 to 177.0)	168.5 (161.0 to 176.0)	170.0 (163.0 to 178.0)	170.0 (162.0 to 176.0)	170.0 (162.0 to 176.0)
	Min to Max	146 to 198	138 to 198	146 to 200	147 to 196	138 to 200	138 to 200
Weight (kg)	n (missing)	299 (104)	340 (175)	268 (119)	279 (110)	1186 (508)	907 (398)
	Mean (SD)	81.9 (17.3)	82.2 (18.5)	84.0 (17.9)	81.9 (17.9)	82.5 (17.9)	82.7 (17.9)
	Median (IQR)	80.0 (70.0 to 93.0)	80.0 (69.0 to 93.5)	82.0 (70.5 to 95.0)	81.0 (70.0 to 92.0)	81.0 (70.0 to 93.0)	81.0 (70.0 to 94.0)
	Min to Max	46 to 150	42 to 150	46 to 145	40 to 164	40 to 164	42 to 150
BMI (kg/m ²)	n (missing)	299 (104)	340 (175)	268 (119)	279 (110)	1186 (508)	907 (398)
	Mean (SD)	28.6 (5.4)	28.7 (5.8)	29.6 (5.8)	28.4 (5.7)	28.8 (5.7)	28.9 (5.6)
	Median (IQR)	28.0 (25.0 to 32.0)	28.0 (25.0 to 31.0)	28.0 (26.0 to 32.0)	28.0 (24.0 to 31.0)	28.0 (25.0 to 32.0)	28.0 (25.0 to 32.0)
	Min to Max	19 to 51	15 to 58	18 to 55	15 to 51	15 to 58	15 to 58
BMI Category, n(%)	n (missing)	299 (104)	340 (175)	268 (119)	279 (110)	1186 (508)	907 (398)
	<19	1 (0.3)	6 (1.8)	1 (0.4)	4 (1.4)	12 (1.0)	8 (0.9)
	19-<25	71 (23.7)	86 (25.3)	59 (22.0)	78 (28.0)	294 (24.8)	216 (23.8)
	25-<30	125 (41.8)	131 (38.5)	100 (37.3)	107 (38.4)	463 (39.0)	356 (39.3)
	30-<40	95 (31.8)	102 (30.0)	94 (35.1)	78 (28.0)	369 (31.1)	291 (32.1)
	>=40	7 (2.3)	15 (4.4)	14 (5.2)	12 (4.3)	48 (4.0)	36 (4.0)
Pulse (bpm)	n (missing)	393 (10)	502 (13)	378 (9)	381 (8)	1654 (40)	1273 (32)
	Mean (SD)	94.0 (29.7)	98.3 (30.4)	101.0 (31.2)	96.8 (30.0)	97.5 (30.4)	97.8 (30.5)
	Median (IQR)	87.0 (70.0 to 116.0)	96.0 (74.0 to 120.0)	96.5 (75.0 to 123.0)	90.0 (75.0 to 115.0)	93.0 (73.0 to 120.0)	94.0 (72.0 to 120.0)
	Min to Max	40 to 195	41 to 200	43 to 180	44 to 178	40 to 200	40 to 200

**Table 05 : Vital signs and life style
Full Analysis Dataset : BELGIUM**

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
Systolic BP (mm Hg)	n (missing)	386 (17)	488 (27)	363 (24)	372 (17)	1609 (85)	1237 (68)
	Mean (SD)	136.3 (21.2)	135.4 (21.0)	136.2 (21.2)	137.6 (22.5)	136.3 (21.4)	135.9 (21.1)
	Median (IQR)	135.5 (120.0 to 150.0)	135.0 (120.0 to 150.0)	133.0 (120.0 to 150.0)	135.0 (120.0 to 150.0)	135.0 (120.0 to 150.0)	135.0 (120.0 to 150.0)
	Min to Max	80 to 219	70 to 210	78 to 232	80 to 221	70 to 232	70 to 232
Diastolic BP (mm Hg)	n (missing)	386 (17)	488 (27)	363 (24)	372 (17)	1609 (85)	1237 (68)
	Mean (SD)	79.9 (13.6)	80.1 (13.3)	81.2 (12.5)	82.2 (14.1)	80.8 (13.4)	80.3 (13.2)
	Median (IQR)	80.0 (70.0 to 90.0)	80.0 (70.0 to 90.0)	80.0 (72.0 to 90.0)	80.0 (73.5 to 90.0)	80.0 (70.0 to 90.0)	80.0 (70.0 to 90.0)
	Min to Max	40 to 140	40 to 125	40 to 117	38 to 145	38 to 145	40 to 140
LVEF (%)	n (missing)	287 (116)	341 (174)	249 (138)	250 (139)	1127 (567)	877 (428)
	Mean (SD)	59.0 (13.5)	57.6 (14.2)	58.7 (13.2)	59.6 (13.3)	58.7 (13.6)	58.4 (13.7)
	Median (IQR)	62.0 (52.0 to 66.0)	60.0 (50.0 to 66.0)	62.0 (52.0 to 67.0)	62.0 (53.0 to 70.0)	61.0 (50.0 to 67.0)	61.0 (50.0 to 66.0)
	Min to Max	15 to 92	10 to 88	15 to 83	20 to 88	10 to 92	10 to 92
LVEF Category, n (n(%))	n (missing)	287 (116)	341 (174)	249 (138)	250 (139)	1127 (567)	877 (428)
	<40%	24 (8.4)	41 (12.0)	23 (9.2)	21 (8.4)	109 (9.7)	88 (10.0)
	>=40%	263 (91.6)	300 (88.0)	226 (90.8)	229 (91.6)	1018 (90.3)	789 (90.0)
History of Hypertension, n(%)	n (missing)	403 (0)	514 (0)	387 (0)	387 (0)	1691 (0)	1304 (0)
	No	121 (30.0)	172 (33.5)	120 (31.0)	123 (31.8)	536 (31.7)	413 (31.7)
	Yes	282 (70.0)	342 (66.5)	267 (69.0)	264 (68.2)	1155 (68.3)	891 (68.3)

**Table 05 : Vital signs and life style
Full Analysis Dataset : BELGIUM**

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
	Unknown	-	1	-	2	3	1
Alcohol Consumption, n(%)	n (missing)	295 (0)	334 (0)	261 (0)	266 (0)	1156 (0)	890 (0)
	Abstinent	139 (47.1)	162 (48.5)	106 (40.6)	107 (40.2)	514 (44.5)	407 (45.7)
	Light	108 (36.6)	118 (35.3)	101 (38.7)	110 (41.4)	437 (37.8)	327 (36.7)
	Moderate	36 (12.2)	43 (12.9)	42 (16.1)	43 (16.2)	164 (14.2)	121 (13.6)
	Heavy	12 (4.1)	11 (3.3)	12 (4.6)	6 (2.3)	41 (3.5)	35 (3.9)
	Unknown	108	181	126	123	538	415
Smoker, n(%)	n (missing)	367 (0)	445 (0)	327 (0)	344 (0)	1483 (0)	1139 (0)
	No	212 (57.8)	260 (58.4)	177 (54.1)	192 (55.8)	841 (56.7)	649 (57.0)
	Ex-smoker	99 (27.0)	134 (30.1)	109 (33.3)	107 (31.1)	449 (30.3)	342 (30.0)
	Current smoker	56 (15.3)	51 (11.5)	41 (12.5)	45 (13.1)	193 (13.0)	148 (13.0)
	Unknown	36	70	60	45	211	166

Table 06 : Clinical History
Full Analysis Dataset : BELGIUM

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
Congestive heart failure, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	No	342 (84.9)	449 (87.2)	344 (88.9)	354 (91.0)	1489 (87.9)	1135 (87.0)
	Yes	61 (15.1)	66 (12.8)	43 (11.1)	35 (9.0)	205 (12.1)	170 (13.0)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	58 (342)	61 (449)	38 (344)	32 (354)	189 (1489)	157 (1135)
	I	5 (8.6)	16 (26.2)	3 (7.9)	4 (12.5)	28 (14.8)	24 (15.3)
	II	28 (48.3)	20 (32.8)	17 (44.7)	5 (15.6)	70 (37.0)	65 (41.4)
	III	20 (34.5)	20 (32.8)	15 (39.5)	22 (68.8)	77 (40.7)	55 (35.0)
	IV	5 (8.6)	5 (8.2)	3 (7.9)	1 (3.1)	14 (7.4)	13 (8.3)
	Unknown	3	5	5	3	16	13
Coronary artery disease, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	No	342 (84.9)	419 (81.4)	335 (86.6)	315 (81.0)	1411 (83.3)	1096 (84.0)
	Yes	61 (15.1)	96 (18.6)	52 (13.4)	74 (19.0)	283 (16.7)	209 (16.0)
Acute coronary syndrome, n(%)	n (missing)	403 (0)	513 (0)	387 (0)	388 (0)	1691 (0)	1303 (0)
	No	368 (91.3)	458 (89.3)	362 (93.5)	356 (91.8)	1544 (91.3)	1188 (91.2)
	Yes	35 (8.7)	55 (10.7)	25 (6.5)	32 (8.2)	147 (8.7)	115 (8.8)
	Unknown	-	2	-	1	3	2
Carotid Occlusive Disease, n(%)	n (missing)	403 (0)	512 (0)	386 (0)	387 (0)	1688 (0)	1301 (0)
	No	388 (96.3)	496 (96.9)	379 (98.2)	378 (97.7)	1641 (97.2)	1263 (97.1)

Table 06 : Clinical History
Full Analysis Dataset : BELGIUM

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
	Yes	15 (3.7)	16 (3.1)	7 (1.8)	9 (2.3)	47 (2.8)	38 (2.9)
	Unknown	-	3	1	2	6	4
PE or DVT, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	387 (0)	1692 (0)	1305 (0)
	No	390 (96.8)	505 (98.1)	379 (97.9)	378 (97.7)	1652 (97.6)	1274 (97.6)
	Yes	13 (3.2)	10 (1.9)	8 (2.1)	9 (2.3)	40 (2.4)	31 (2.4)
	Unknown	-	-	-	2	2	-
Other Thromboemboli sm, n(%)	n (missing)	397 (6)	0 (515)	0 (387)	0 (389)	397 (1297)	397 (908)
	No	391 (98.5)	-	-	-	391 (98.5)	391 (98.5)
	Yes	6 (1.5)	-	-	-	6 (1.5)	6 (1.5)
Systemic Embolization, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	387 (0)	1692 (0)	1305 (0)
	No	399 (99.0)	512 (99.4)	382 (98.7)	383 (99.0)	1676 (99.1)	1293 (99.1)
	Yes	4 (1.0)	3 (0.6)	5 (1.3)	4 (1.0)	16 (0.9)	12 (0.9)
	Unknown	-	-	-	2	2	-
Coronary Artery Bypass Graft, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	No	382 (94.8)	487 (94.6)	376 (97.2)	372 (95.6)	1617 (95.5)	1245 (95.4)
	Yes	21 (5.2)	28 (5.4)	11 (2.8)	17 (4.4)	77 (4.5)	60 (4.6)
Stroke/TIA, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	No	359 (89.1)	467 (90.7)	350 (90.4)	350 (90.0)	1526 (90.1)	1176 (90.1)

Table 06 : Clinical History
Full Analysis Dataset : BELGIUM

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
	Yes	44 (10.9)	48 (9.3)	37 (9.6)	39 (10.0)	168 (9.9)	129 (9.9)
Stroke, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	No	380 (94.3)	489 (95.0)	365 (94.3)	371 (95.4)	1605 (94.7)	1234 (94.6)
	Yes	23 (5.7)	26 (5.0)	22 (5.7)	18 (4.6)	89 (5.3)	71 (5.4)
History of Bleeding, n(%)	n (missing)	403 (0)	515 (0)	385 (0)	389 (0)	1692 (0)	1303 (0)
	No	393 (97.5)	501 (97.3)	377 (97.9)	374 (96.1)	1645 (97.2)	1271 (97.5)
	Yes	10 (2.5)	14 (2.7)	8 (2.1)	15 (3.9)	47 (2.8)	32 (2.5)
	Unknown	-	-	2	-	2	2
Hypercholester olaemia, n(%)	n (missing)	403 (0)	505 (0)	377 (0)	376 (0)	1661 (0)	1285 (0)
	No	190 (47.1)	220 (43.6)	172 (45.6)	153 (40.7)	735 (44.3)	582 (45.3)
	Yes	213 (52.9)	285 (56.4)	205 (54.4)	223 (59.3)	926 (55.7)	703 (54.7)
	Unknown	-	10	10	13	33	20
Diabetes, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	No	342 (84.9)	427 (82.9)	323 (83.5)	323 (83.0)	1415 (83.5)	1092 (83.7)
	Type I	5 (1.2)	9 (1.7)	8 (2.1)	-	22 (1.3)	22 (1.7)
	Type II	56 (13.9)	79 (15.3)	56 (14.5)	66 (17.0)	257 (15.2)	191 (14.6)
Diabetes, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	No	342 (84.9)	427 (82.9)	323 (83.5)	323 (83.0)	1415 (83.5)	1092 (83.7)
	Yes	61 (15.1)	88 (17.1)	64 (16.5)	66 (17.0)	279 (16.5)	213 (16.3)
Cirrhosis, n(%)	n (missing)	402 (0)	508 (0)	378 (0)	387 (0)	1675 (0)	1288 (0)
	No	400 (99.5)	504 (99.2)	377 (99.7)	387 (100.0)	1668 (99.6)	1281 (99.5)
	Yes	2 (0.5)	4 (0.8)	1 (0.3)	-	7 (0.4)	7 (0.5)
	Unknown	1	7	9	2	19	17

Table 06 : Clinical History
Full Analysis Dataset : BELGIUM

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
Dementia, n(%)	n (missing)	403 (0)	514 (0)	387 (0)	388 (0)	1692 (0)	1304 (0)
	No	400 (99.3)	511 (99.4)	383 (99.0)	387 (99.7)	1681 (99.3)	1294 (99.2)
	Yes	3 (0.7)	3 (0.6)	4 (1.0)	1 (0.3)	11 (0.7)	10 (0.8)
	Unknown	-	1	-	1	2	1
Hyperthyroidism, n(%)	n (missing)	403 (0)	512 (0)	385 (0)	388 (0)	1688 (0)	1300 (0)
	No	388 (96.3)	492 (96.1)	376 (97.7)	381 (98.2)	1637 (97.0)	1256 (96.6)
	Yes	15 (3.7)	20 (3.9)	9 (2.3)	7 (1.8)	51 (3.0)	44 (3.4)
	Unknown	-	3	2	1	6	5
Hypothyroidism, n(%)	n (missing)	403 (0)	511 (0)	385 (0)	387 (0)	1686 (0)	1299 (0)
	No	388 (96.3)	484 (94.7)	373 (96.9)	372 (96.1)	1617 (95.9)	1245 (95.8)
	Yes	15 (3.7)	27 (5.3)	12 (3.1)	15 (3.9)	69 (4.1)	54 (4.2)
	Unknown	-	4	2	2	8	6
Vascular Disease, n(%)	n (missing)	403 (0)	514 (1)	387 (0)	388 (1)	1692 (2)	1304 (1)
	No	341 (84.6)	418 (81.3)	344 (88.9)	329 (84.8)	1432 (84.6)	1103 (84.6)
	Yes	62 (15.4)	96 (18.7)	43 (11.1)	59 (15.2)	260 (15.4)	201 (15.4)
Moderate to Severe CKD, n(%)	n (missing)	403 (0)	515 (0)	387 (0)	389 (0)	1694 (0)	1305 (0)
	No	346 (85.9)	443 (86.0)	346 (89.4)	336 (86.4)	1471 (86.8)	1135 (87.0)
	Yes	57 (14.1)	72 (14.0)	41 (10.6)	53 (13.6)	223 (13.2)	170 (13.0)

**Table 07 : Treatment for stroke prophylaxis
Full Analysis Dataset : BELGIUM**

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
Baseline Treatment, n(%)	n (missing)	401 (0)	511 (0)	386 (0)	386 (0)	1684 (0)	1298 (0)
	VKA	60 (15.0)	70 (13.7)	37 (9.6)	18 (4.7)	185 (11.0)	167 (12.9)
	VKA+AP	21 (5.2)	17 (3.3)	7 (1.8)	12 (3.1)	57 (3.4)	45 (3.5)
	FXA	99 (24.7)	201 (39.3)	201 (52.1)	188 (48.7)	689 (40.9)	501 (38.6)
	FXA+AP	32 (8.0)	45 (8.8)	19 (4.9)	51 (13.2)	147 (8.7)	96 (7.4)
	DTI	71 (17.7)	56 (11.0)	44 (11.4)	51 (13.2)	222 (13.2)	171 (13.2)
	DTI+AP	10 (2.5)	16 (3.1)	7 (1.8)	8 (2.1)	41 (2.4)	33 (2.5)
	AP	64 (16.0)	59 (11.5)	35 (9.1)	25 (6.5)	183 (10.9)	158 (12.2)
	NONE	44 (11.0)	47 (9.2)	36 (9.3)	33 (8.5)	160 (9.5)	127 (9.8)
	Unknown	2	4	1	3	10	7
	VKA±AP	81 (20.2)	87 (17.0)	44 (11.4)	30 (7.8)	242 (14.4)	212 (16.3)
	FXA±AP	131 (32.7)	246 (48.1)	220 (57.0)	239 (61.9)	836 (49.6)	597 (46.0)
	DTI±AP	81 (20.2)	72 (14.1)	51 (13.2)	59 (15.3)	263 (15.6)	204 (15.7)
	FXA/DTI	170 (42.4)	257 (50.3)	245 (63.5)	239 (61.9)	911 (54.1)	672 (51.8)
	FXA/DTI+AP	42 (10.5)	61 (11.9)	26 (6.7)	59 (15.3)	188 (11.2)	129 (9.9)
	FXA/DTI±AP	212 (52.9)	318 (62.2)	271 (70.2)	298 (77.2)	1099 (65.3)	801 (61.7)
	AC	230 (57.4)	327 (64.0)	282 (73.1)	257 (66.6)	1096 (65.1)	839 (64.6)
	AC+AP	63 (15.7)	78 (15.3)	33 (8.5)	71 (18.4)	245 (14.5)	174 (13.4)
	AC±AP	293 (73.1)	405 (79.3)	315 (81.6)	328 (85.0)	1341 (79.6)	1013 (78.0)

Table 08: Treatment
Full Analysis Dataset : BELGIUM

	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
Anti-platelet (non mutually exclusive groups)						
ADP receptor/P2Y12 inhibitors	22 (5.5)	17 (3.3)	8 (2.1)	24 (6.2)	71 (4.2)	47 (3.6)
Cox inhibitors	3 (0.7)	21 (4.1)	4 (1.0)	5 (1.3)	33 (1.9)	28 (2.1)
ASA	109 (27.0)	114 (22.1)	61 (15.8)	83 (21.3)	367 (21.7)	284 (21.8)
Anticoagulant drugs (non mutually exclusive groups)						
VKA	81 (20.1)	89 (17.3)	44 (11.4)	30 (7.7)	244 (14.4)	214 (16.4)
FXa	133 (33.0)	249 (48.3)	220 (56.8)	242 (62.2)	844 (49.8)	602 (46.1)
DTI	83 (20.6)	73 (14.2)	51 (13.2)	62 (15.9)	269 (15.9)	207 (15.9)
Heparinoid	8 (2.0)	5 (1.0)	-	-	13 (0.8)	13 (1.0)
Heparins	78 (19.4)	78 (15.1)	49 (12.7)	43 (11.1)	248 (14.6)	205 (15.7)
Other	3 (0.7)	2 (0.4)	-	-	5 (0.3)	5 (0.4)

Table 09 : Risk scores
Full Analysis Dataset : BELGIUM

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
CHADS2 Score	n (missing)	395 (8)	503 (12)	379 (8)	383 (6)	1660 (34)	1277 (28)
	Mean (SD)	1.8 (1.1)	1.7 (1.1)	1.7 (1.1)	1.7 (1.1)	1.7 (1.1)	1.7 (1.1)
	Median (IQR)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)
	Min to Max	0 to 5	0 to 6	0 to 5	0 to 6	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	395 (8)	503 (12)	379 (8)	383 (6)	1660 (34)	1277 (28)
	0	34 (8.6)	63 (12.5)	44 (11.6)	44 (11.5)	185 (11.1)	141 (11.0)
	1	131 (33.2)	179 (35.6)	145 (38.3)	145 (37.9)	600 (36.1)	455 (35.6)
	2	148 (37.5)	162 (32.2)	119 (31.4)	117 (30.5)	546 (32.9)	429 (33.6)
	3	57 (14.4)	70 (13.9)	44 (11.6)	52 (13.6)	223 (13.4)	171 (13.4)
	4	16 (4.1)	20 (4.0)	21 (5.5)	21 (5.5)	78 (4.7)	57 (4.5)
	5	9 (2.3)	8 (1.6)	6 (1.6)	3 (0.8)	26 (1.6)	23 (1.8)
	6	-	1 (0.2)	-	1 (0.3)	2 (0.1)	1 (0.1)
CHA2DS2-VASc Score	n (missing)	395 (8)	502 (13)	379 (8)	380 (9)	1656 (38)	1276 (29)
	Mean (SD)	3.2 (1.5)	3.1 (1.6)	3.0 (1.6)	3.1 (1.5)	3.1 (1.5)	3.1 (1.6)
	Median (IQR)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 8	0 to 8	0 to 8	0 to 8	0 to 8	0 to 8
CHA2DS2-VASc score categories, n(%)	n (missing)	395 (8)	502 (13)	379 (8)	380 (9)	1656 (38)	1276 (29)
	0	9 (2.3)	27 (5.4)	15 (4.0)	14 (3.7)	65 (3.9)	51 (4.0)
	1	45 (11.4)	53 (10.6)	52 (13.7)	44 (11.6)	194 (11.7)	150 (11.8)
	2	69 (17.5)	104 (20.7)	86 (22.7)	82 (21.6)	341 (20.6)	259 (20.3)
	3	107 (27.1)	116 (23.1)	85 (22.4)	92 (24.2)	400 (24.2)	308 (24.1)
	4	100 (25.3)	107 (21.3)	80 (21.1)	88 (23.2)	375 (22.6)	287 (22.5)

Table 09 : Risk scores
Full Analysis Dataset : BELGIUM

Variable	Statistics	Cohort 2 (N=403) (n %)	Cohort 3 (N=515) (n %)	Cohort 4 (N=387) (n %)	Cohort 5 (N=389) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1694)	Total Prospective patients Cohorts 1 to 4 (N=1305)
	5	40 (10.1)	66 (13.1)	37 (9.8)	37 (9.7)	180 (10.9)	143 (11.2)
	6-9	25 (6.3)	29 (5.8)	24 (6.3)	23 (6.1)	101 (6.1)	78 (6.1)
HAS-BLED score	n (missing)	268 (135)	321 (194)	246 (141)	255 (134)	1090 (604)	835 (470)
	Mean (SD)	1.6 (1.0)	1.5 (0.9)	1.4 (0.9)	1.5 (0.9)	1.5 (0.9)	1.5 (0.9)
	Median (IQR)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 4	0 to 4	0 to 4	0 to 5	0 to 5	0 to 4
HAS-BLED score categories, n(%)	n (missing)	268 (135)	321 (194)	246 (141)	255 (134)	1090 (604)	835 (470)
	0	34 (12.7)	37 (11.5)	31 (12.6)	30 (11.8)	132 (12.1)	102 (12.2)
	1	102 (38.1)	135 (42.1)	116 (47.2)	109 (42.7)	462 (42.4)	353 (42.3)
	2	87 (32.5)	98 (30.5)	77 (31.3)	82 (32.2)	344 (31.6)	262 (31.4)
	3	38 (14.2)	45 (14.0)	18 (7.3)	28 (11.0)	129 (11.8)	101 (12.1)
	4	7 (2.6)	6 (1.9)	4 (1.6)	5 (2.0)	22 (2.0)	17 (2.0)
	5	-	-	-	1 (0.4)	1 (0.1)	-

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : BELGIUM**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 2	0	-	-	1	12.5	-	-	-	-	1	12.5	1	12.5	-	-	5	62.5	1
	1	7	15.9	3	6.8	8	18.2	-	-	3	6.8	-	-	13	29.5	10	22.7	1
	2	11	15.9	1	1.4	15	21.7	4	5.8	15	21.7	1	1.4	14	20.3	8	11.6	-
	3	17	15.9	4	3.7	24	22.4	17	15.9	21	19.6	3	2.8	11	10.3	10	9.3	-
	4	10	10	5	5	38	38	7	7	21	21	-	-	13	13	6	6	-
	5	7	17.5	2	5	9	22.5	3	7.5	8	20	4	10	5	12.5	2	5	-
6-9	6	24	4	16	5	20	1	4	1	4	1	4	7	28	-	-	-	
Cohort 3	0	2	8	2	8	5	20	1	4	-	-	-	-	8	32	7	28	2
	1	14	26.4	3	5.7	12	22.6	3	5.7	5	9.4	-	-	9	17	7	13.2	-
	2	17	16.3	4	3.8	43	41.3	7	6.7	15	14.4	2	1.9	6	5.8	10	9.6	-
	3	12	10.4	1	0.9	54	47	9	7.8	8	7	5	4.3	13	11.3	13	11.3	1
	4	10	9.4	1	0.9	48	45.3	13	12.3	14	13.2	5	4.7	10	9.4	5	4.7	1
	5	8	12.1	4	6.1	22	33.3	8	12.1	11	16.7	2	3	10	15.2	1	1.5	-
6-9	4	13.8	1	3.4	12	41.4	4	13.8	2	6.9	2	6.9	2	6.9	2	6.9	-	
Cohort 4	0	-	-	1	6.7	-	-	1	6.7	5	33.3	-	-	5	33.3	3	20	-
	1	15	28.8	2	3.8	13	25	-	-	3	5.8	1	1.9	10	19.2	8	15.4	-
	2	7	8.1	-	-	48	55.8	3	3.5	11	12.8	1	1.2	5	5.8	11	12.8	-
	3	5	6	-	-	56	66.7	6	7.1	7	8.3	1	1.2	2	2.4	7	8.3	1
	4	4	5	2	2.5	48	60	3	3.8	10	12.5	2	2.5	8	10	3	3.8	-
	5	1	2.7	2	5.4	21	56.8	3	8.1	4	10.8	1	2.7	3	8.1	2	5.4	-
6-9	4	16.7	-	-	14	58.3	3	12.5	3	12.5	-	-	-	-	-	-	-	
Cohort 5	0	1	7.1	-	-	5	35.7	1	7.1	2	14.3	-	-	3	21.4	2	14.3	-
	1	2	4.5	2	4.5	16	36.4	5	11.4	3	6.8	-	-	7	15.9	9	20.5	-
	2	5	6.1	3	3.7	43	52.4	8	9.8	7	8.5	2	2.4	7	8.5	7	8.5	-
	3	3	3.3	2	2.2	52	57.1	12	13.2	15	16.5	-	-	1	1.1	6	6.6	1
	4	2	2.3	1	1.1	44	50	13	14.8	16	18.2	3	3.4	4	4.5	5	5.7	-
	5	2	5.6	4	11.1	17	47.2	4	11.1	4	11.1	1	2.8	2	5.6	2	5.6	1
6-9	2	9.1	-	-	8	36.4	6	27.3	3	13.6	1	4.5	-	-	2	9.1	1	

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : BELGIUM**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total Prospective patients Cohorts 1 to 5	0	3	4.8	4	6.5	10	16.1	3	4.8	8	12.9	1	1.6	16	25.8	17	27.4	3
	1	38	19.7	10	5.2	49	25.4	8	4.1	14	7.3	1	0.5	39	20.2	34	17.6	1
	2	40	11.7	8	2.3	149	43.7	22	6.5	48	14.1	6	1.8	32	9.4	36	10.6	-
	3	37	9.3	7	1.8	186	46.9	44	11.1	51	12.8	9	2.3	27	6.8	36	9.1	3
	4	26	7	9	2.4	178	47.6	36	9.6	61	16.3	10	2.7	35	9.4	19	5.1	1
	5	18	10.1	12	6.7	69	38.5	18	10.1	27	15.1	8	4.5	20	11.2	7	3.9	1
	6-9	16	16	5	5	39	39	14	14	9	9	4	4	9	9	4	4	1
Total Prospective patients Cohorts 1 to 4	0	2	4.2	4	8.3	5	10.4	2	4.2	6	12.5	1	2.1	13	27.1	15	31.3	3
	1	36	24.2	8	5.4	33	22.1	3	2	11	7.4	1	0.7	32	21.5	25	16.8	1
	2	35	13.5	5	1.9	106	40.9	14	5.4	41	15.8	4	1.5	25	9.7	29	11.2	-
	3	34	11.1	5	1.6	134	43.8	32	10.5	36	11.8	9	2.9	26	8.5	30	9.8	2
	4	24	8.4	8	2.8	134	46.9	23	8	45	15.7	7	2.4	31	10.8	14	4.9	1
	5	16	11.2	8	5.6	52	36.4	14	9.8	23	16.1	7	4.9	18	12.6	5	3.5	-
	6-9	14	17.9	5	6.4	31	39.7	8	10.3	6	7.7	3	3.8	9	11.5	2	2.6	-

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : BELGIUM**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 2	0	9	27.3	-	-	7	21.2	-	-	4	12.1	-	-	-	-	13	39.4	1
	1	16	15.7	2	2	45	44.1	2	2	13	12.7	1	1	9	8.8	14	13.7	-
	2	9	10.3	3	3.4	15	17.2	15	17.2	17	19.5	3	3.4	23	26.4	2	2.3	-
	3	6	15.8	4	10.5	9	23.7	4	10.5	3	7.9	4	10.5	7	18.4	1	2.6	-
	4-9	2	28.6	2	28.6	-	-	1	14.3	-	-	1	14.3	1	14.3	-	-	-
Cohort 3	0	14	37.8	-	-	13	35.1	-	-	2	5.4	-	-	-	-	8	21.6	-
	1	19	14.2	5	3.7	70	52.2	2	1.5	15	11.2	-	-	11	8.2	12	9	1
	2	7	7.3	5	5.2	35	36.5	14	14.6	10	10.4	7	7.3	15	15.6	3	3.1	2
	3	6	13.3	4	8.9	14	31.1	10	22.2	1	2.2	2	4.4	5	11.1	3	6.7	-
	4-9	1	16.7	-	-	-	-	3	50	1	16.7	-	-	1	16.7	-	-	-
Cohort 4	0	13	41.9	-	-	6	19.4	-	-	3	9.7	-	-	-	-	9	29	-
	1	7	6	1	0.9	81	69.8	1	0.9	6	5.2	-	-	9	7.8	11	9.5	-
	2	5	6.5	3	3.9	37	48.1	8	10.4	8	10.4	3	3.9	7	9.1	6	7.8	-
	3	1	5.6	-	-	12	66.7	2	11.1	1	5.6	-	-	2	11.1	-	-	-
	4-9	-	-	-	-	2	50	1	25	-	-	-	-	1	25	-	-	-
Cohort 5	0	-	-	-	-	21	70	-	-	4	13.3	-	-	-	-	5	16.7	-
	1	4	3.7	3	2.8	65	60.2	4	3.7	17	15.7	1	0.9	8	7.4	6	5.6	1
	2	1	1.2	3	3.7	36	44.4	24	29.6	4	4.9	1	1.2	5	6.2	7	8.6	1
	3	-	-	2	7.4	9	33.3	7	25.9	2	7.4	2	7.4	3	11.1	2	7.4	1
	4-9	1	16.7	1	16.7	2	33.3	1	16.7	-	-	-	-	1	16.7	-	-	-
Total Prospective patients Cohorts 1 to 5	0	36	27.5	-	-	47	35.9	-	-	13	9.9	-	-	-	-	35	26.7	1
	1	46	10	11	2.4	261	56.7	9	2	51	11.1	2	0.4	37	8	43	9.3	2
	2	22	6.5	14	4.1	123	36.1	61	17.9	39	11.4	14	4.1	50	14.7	18	5.3	3
	3	13	10.2	10	7.8	44	34.4	23	18	7	5.5	8	6.3	17	13.3	6	4.7	1

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : BELGIUM**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
	4-9	4	17.4	3	13	4	17.4	6	26.1	1	4.3	1	4.3	4	17.4	-	-	-
Total Prospective patients Cohorts 1 to 4	0	36	35.6	-	-	26	25.7	-	-	9	8.9	-	-	-	-	30	29.7	1
	1	42	11.9	8	2.3	196	55.7	5	1.4	34	9.7	1	0.3	29	8.2	37	10.5	1
	2	21	8.1	11	4.2	87	33.5	37	14.2	35	13.5	13	5	45	17.3	11	4.2	2
	3	13	12.9	8	7.9	35	34.7	16	15.8	5	5	6	5.9	14	13.9	4	4	-
	4-9	3	17.6	2	11.8	2	11.8	5	29.4	1	5.9	1	5.9	3	17.6	-	-	-

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : BELGIUM**

Variable	Statistics	Cohort 2 (N=81) (n %)	Cohort 3 (N=87) (n %)	Cohort 4 (N=44) (n %)	Total Prospective patients Cohorts 1 to 4 (N=212)
TTR value, n(%)	n (missing)	49 (32)	43 (44)	14 (30)	106 (106)
	<65	38 (77.6)	34 (79.1)	9 (64.3)	81 (76.4)
	>=65	11 (22.4)	9 (20.9)	5 (35.7)	25 (23.6)
TTR	n (missing)	49 (32)	43 (44)	14 (30)	106 (106)
	Mean (SD)	46.7 (21.0)	44.0 (23.9)	53.5 (26.4)	46.5 (22.9)
	Median (IQR)	47.9 (30.1 to 58.1)	40.2 (24.9 to 59.9)	58.0 (33.9 to 75.7)	47.6 (29.2 to 61.8)
	Min to Max	0.0 to 93.7	0.0 to 100.0	0.0 to 87.3	0.0 to 100.0
INR value, n(%)	n	671	513	212	1396
	2-3	286 (42.6)	210 (40.9)	103 (48.6)	599 (42.9)
	<2	256 (38.2)	180 (35.1)	74 (34.9)	510 (36.5)
	>3	129 (19.2)	123 (24.0)	35 (16.5)	287 (20.6)
INR	n	671	513	212	1396
	Mean (SD)	2.4 (0.9)	2.5 (1.1)	2.3 (0.9)	2.4 (1.0)
	Median (IQR)	2.2 (1.7 to 2.8)	2.3 (1.8 to 3.0)	2.2 (1.7 to 2.8)	2.2 (1.7 to 2.9)
	Min to Max	1.0 to 7.5	1.0 to 10.0	1.0 to 7.0	1.0 to 10.0

**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : BELGIUM**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		1305	64	5.08	(3.98 to 6.49)
	Cardiovascular death	1305	18	1.43	(0.90 to 2.27)
	Non-Cardiovascular death	1305	36	2.86	(2.06 to 3.96)
	Undetermined cause	1305	10	0.79	(0.43 to 1.48)
Stroke/SE		1305	15	1.20	(0.72 to 1.98)
Major bleed		1305	18	1.44	(0.91 to 2.28)
Acute coronary syndrome		1305	13	1.04	(0.60 to 1.78)
Congestive Heart Failure		1305	25	2.01	(1.36 to 2.97)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : BELGIUM**

		BELGIUM		
Outcome	Cause	N	Events	%
Cardiovascular causes	Myocardial infarction	18	3	16.67
	Ischaemic stroke	18	2	11.11
	Congestive heart failure	18	5	27.78
	Sudden or unwitnessed death	18	5	27.78
	Other	18	3	16.67
Non-cardiovascular causes	Accidental / trauma	36	1	2.78
	Respiratory failure	36	10	27.78
	Infection/sepsis	36	9	25.00
	Malignancy	36	6	16.67
	Other	36	10	27.78

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset :BELGIUM**

OUTCOME	BELGIUM		
	N	Events	%
Stroke(not including systemic embolism)	1305	12	0.92
Primary Ischemic Stroke	1305	9	0.69
<i>of which secondary hemorrhagic ischemic</i>	1305	1	0.08
Primary intracerebral hemorrhage*	1305	1	0.08
<i>Intracerebral</i>	1305	1	0.08
Undetermined	1305	2	0.15

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : BELGIUM**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	51	50.27	0	-	-
1	150	148.22	1	0.68	(0.10 to 4.79)
2	259	252.51	8	3.17	(1.58 to 6.34)
3	308	297.91	16	5.37	(3.29 to 8.77)
4+	508	484.60	36	7.43	(5.36 to 10.30)
Unknown	29	25.99	3	11.54	(3.72 to 35.79)

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : BELGIUM**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	51	49.67	1	2.01	(0.28 to 14.29)
1	150	148.22	1	0.68	(0.10 to 4.79)
2	259	250.85	3	1.20	(0.39 to 3.71)
3	308	296.82	5	1.69	(0.70 to 4.05)
4+	508	483.04	5	1.04	(0.43 to 2.49)
Unknown	29	25.99	0	-	-

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : BELGIUM**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	51	50.27	0	-	-
1	150	147.52	1	0.68	(0.10 to 4.81)
2	259	250.95	3	1.20	(0.39 to 3.71)
3	308	294.92	5	1.70	(0.71 to 4.07)
4+	508	481.46	9	1.87	(0.97 to 3.59)
Unknown	29	25.99	0	-	-